Comparison of the safety and immunogenicity of the lyophilized Merieux seed and the World Health Organization working reference BCG vaccines in school-aged children in Senegal

Vaccine

Volumn 17, Issue 2, 1999, Pages 105-109

  Guerin N ^a   Teulieres L ^b   Noba, A ^c   Schlumberger, M ^d   Bregere P ^e   Chauvin, P ^d  

^a Centre International de l'Enfance   (France)

^b Syndicat National de l'Industrie Pharmaceutique   (France)

^c MINISTÈRE DE LA SANTÉ   (Senegal)

^d Assoc pour l'Aide a la Medecine P   (France)

^e Pasteur Merieux Connaught   (France)

Author keywords

BCG vaccine; Child; Mycobacterium bovis; Reference standards; Senegal; Tuberculin test; Tuberculosis; World Health Organisation

Indexed keywords

BCG VACCINE;

ARTICLE; BCG VACCINATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG SAFETY; DRUG SCREENING; HUMAN; IMMUNOGENICITY; INTRADERMAL DRUG ADMINISTRATION; MULTICENTER STUDY; MYCOBACTERIUM BOVIS; NORMAL HUMAN; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; SCAR FORMATION; SCHOOL CHILD; SENEGAL; STANDARD; TUBERCULIN TEST; WORLD HEALTH ORGANIZATION;

BCG VACCINE; CHILD; CICATRIX; FREEZE DRYING; HUMANS; REFERENCE STANDARDS; SAFETY; SENEGAL; TUBERCULIN TEST; WORLD HEALTH ORGANIZATION;

EID: 0344783803     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00186-8     Document Type: Article

References (12)

1. Gheorghiu M. The present and future role of BCG in tuberculosis control. Biologicals. 18:1990;135-141.
2. Schwoebel V., Hubert B., Grosset J. Impact on tuberculosis meningitis in France in 1990. Lancet. 340:1992;611.
3. Colditz G.A., Berkey C.S., Mosteller F.et al. The efficacy of Bacille Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analysis of the published literature. Pediatrics. 96:1995;29-35.
4. Rodrigues L.C., Diwan V.K., Wheller J.G. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis a meta-analysis. International Journal of Epidemiology. 22:1993;1154-1158.
5. WHO, Special Programme on AIDS and Expanded Programme on Immunization, Joint statement. Consultation on human immunodeficiency virus (HIV) and routine childhood immunization. Weekly Epidemiology Record, 1987, 62, 297-299.
6. Milstien J.B., Gibson J.J. Quality control of BCG vaccine by WHO: A review of factors that may influence vaccine effectiveness and safety. Bulletin WHO. 68:1990;93-108.
7. Comité OMS d'experts de la standardisation biologique. Normes pour les substances biologiques. OMS Geneva, 1987, 845. Sér. de Rap. tech., No. 745.
8. Teulières L., Diouf M.A., Chaud P., Saint-Cyr A., Saliou P. Comparative trial of administration of half (0.05 mg) and quarter (0.025 mg) dose of intradermal Pasteur BCG on 291 infants from birth to 1 year in French Guyana. Vaccine. 9:1991;521-524.
9. Chan SL, Allan G, Pio A et al. Comparison of the efficacy of two strains of BCG vaccine for prevention of tuberculosis among newborn children in Hong Kong. XXVIth Conference on Tuberculosis and Respiratory Diseases, Singapore, 4-6 November 1986. In: IUAT Bull 1986;61:38.
10. Chan SL, Allan G, Pio A et al. Comparison of the efficacy of two strains of BCG vaccine for prevention of tuberculosis among newborn children in Hong Kong. XXVIth Conference on Tuberculosis and Respiratory Diseases, Singapore, 4-6 November 1986. In: IUAT Bull 1986;61:38.
11. Milstien J, The Immunological Basis for Immunization: Tuberculosis, WHO/EPI/GEN/93.15. WHO, Geneva, 1993.
12. Palmer C.E., Edwards L.B. Sensitivity to mycobacterial PPD antigens with some laboratory evidence of its significance. Tuberkulose. 18:1968;193-200.